Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: Implications for antigen-specific immunotherapy

Blood

Volumn 90, Issue 6, 1997, Pages 2406-2416

  Ferrari, G ^b   Berend, C ^b   Ottinger, J ^b   Dodge, R ^b   Bartlett, J ^b   Toso, J ^b   Moody, D ^b   Tartaglia, J ^b   Cox, William I ^b   Paoletti, E ^b   Weinhold, K J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAG PROTEIN; GLYCOPROTEIN GP 120; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 7; VIRUS VECTOR;

ANTIGEN SPECIFICITY; ARTICLE; CANARYPOX; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN TISSUE; IMMUNOSTIMULATION; IMMUNOTHERAPY; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0030829060     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.6.2406     Document Type: Article

References (65)

1. Jason J, Lui K-J, Ragni MV, Hessol NA, Darrow WW: Risk of developing AIDS in HIV-infected cohorts of hemophiliac and homosexual men. JAMA 261:725, 1989
2. Rutherford GW, Lifson AR, Hessol NA, Darrow WW, O'Malley PM, Buchbinder SP, Barnhart JL, Bodecker TW, Cannon L, Doll LS, Holmberg SD, Harrison JS, Rogers MF, Werdegar D, Jaffe HW: Course of HIV-1 infection in a cohort of homosexual and bisexual men: An 11 year follow up study. Br Med J 301:1183, 1990
3. Fauci AS, Schnittman SM, Poli G, Koenig S, Pantaleo G: Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection. Ann Intern Med 114:678, 1991
4. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, Fauci AS: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362:355, 1993
5. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, Haase AT: Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 362:359, 1993
6. McMichael AJ, Gotch FM, Noble GR, Beare PA: Cytotoxic T-cell immunity to influenza. N Engl J Med 309:13, 1983
7. Riddel SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257:238, 1992
8. Koup RA, Safrit JF, Cao Y, Andrews CA, McLeod G, Borkowski W, Farthing C, Ho DD: Temporal association of cellular immune response with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68:4650, 1994
9. + cytotoxic T lymphocyte activity associated with control viremia in primary human immunodeficiency virus type 1 infection. J Virol 68:6103, 1994
10. + T lymphocytes of patients with AIDS maintain normal broad cytolytic function despite the loss of human immunodeficiency virus-specific cytotoxicity. Proc Natl Acad Sci USA 87:4818, 1990
11. Carmichael A, Jin X, Sisson P, Borysiewicz L: Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocytes (CTL) response at different stages of HIV-1 infection: Differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 177:249, 1993
12. Klein MR, van Baalen CA, Holwerda AM, Kerkhof Garde SR, Bende RJ, Keet IPM, Eeftinck-Schattenkerk J-KM, Osterhaus ADME, Scuitemaker H, Miedema F: Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 181:1365, 1995
13. Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S, Whitby D, Sabally S, Gallimore A, Corrah T, Takiguchi M, Schultz T, McMichael A, Whittle H: HIV-specific citotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1:59, 1995
14. Cheynier R, Langlade-Demoyen P, Marescot M-R, Blanche S, Blondin G, Wain-Hobson S, Griscelli C, Vilmer E, Plata F: Cytotoxic T lymphocyte responses in the peripheral blood of children born to HIV-1 infected mother. Eur J Immunol 22:2211, 1993
15. Rowland-Jones S, Nixon DS, Aldhous MC, Gotch F, Aryoshi K, Hallam N, Kroll JS, Froebel K, McMichael AJ: HIV-specific CTL activity in an HIV-exposed but uninfected infant. Lancet 341:860, 1993
16. Weinhold KJ, Tartaglia J, Paoletti E, Graham B, Scwartz D, McElhart J, Roberts N, Gorse G: Specific activation strategies for amplification of low CTL signals. AIDS Res Hum Retroviruses 8:1373, 1992
17. Ferrari G, King K, Rathbun K, Place CA, Packard MV, Bartlett JA, Bolognesi DP, Weinhold KJ: IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp). Clin Exp Immunol 101:1995
18. Redfield RR, Wright DG, James WD, Jones TS, Brown C, Burke DS: Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 316:673, 1987
19. Cadoz M, Strady A, Meignier B, Taylor J, Tartaglia J, Paoletti E, Plotkin S: Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 339:1429, 1992
20. Tartaglia J, Jarret O, Neil JC, Desmettre P, Paoletti E: Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J Virol 67:2370, 1993
21. Abimiku AG, Franchini G, Tartaglia G, Aldrich K, Myagkikh M, Markham PD, Chong P, Klein M, Kieny M-P, Paoletti E, Gallo RC, Robert-Guroff M: HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat Med 1:321, 1995
22. Egan MA, Pavlat WA, Tartaglia J, Paoletti E, Weinhold KJ, Clements ML, Siliciano RF: Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted Canarypox vector (ALVAC) carrying the HIV-1 MN env gene. J Infect Dis 171:1623, 1995
23. Weinhold KJ, Rathbun K, Humphrey W, Corr K, Berend C, Ferrari G: Cytolytic responses elicited in phase I vaccine trials: The AVEG experience, in Girard M, Dodet B (eds): Retroviruses of Human AIDS and Related Animal Disease. Proceedings of the Tenth Colloque des Cent Gardes. Paris, France, Elsevier, 1996
24. Tartaglia J, Cox WI, Taylor J, Perkus M, Riviere M, Meignier B, Paoletti E: Higly attenuated poxvirus vectors. AIDS Res Hum Retroviruses 8:1445, 1992
25. Tartaglia J, Taylor J, Cox WI, Audonnet J-C, Perkus ME, Paoletti E, Radaelli A, De Giuli Morghen C, Meignier B, Riviere M, Weinhold KJ: Novel poxvirus strains as research tools and vaccine vectors, in Coff CW, Wong-Staal FW, Kennedy RC (eds): AIDS Research Reviews. New York, NY, Marcel Dekker, 1993
26. Cox WI, Tartaglia J, Paoletti E: Induction of cytotoxic T lymphocytes by recombinant Canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology 195:845, 1993
27. Perkus ME, Kauffman EB, Taylor J, Mercer S, Smith D, Van der Hoeven J, Paoletti E: Methodology of using vaccinia virus to express foreign genes in tissue culture. J Tiss Cult Methods 15:72, 1993
28. Gurgo C, Guo H-G, Franchini G, Aldovini A, Collati E, Farrell K, Wong-Staal F, Gallo RC, Reitz MSJ: Envelope sequence of two new United States HIV-1 isolates. Virology 164:531, 1988
29. Ratner L, Haseltine W, Patarca R, Livak KJ, Starcich B, Josephs SF, Doran ER, Rafalski JA, Whitehorn EA, Baumeister K, Ivanoff L, Petteway SR, Pearson ML, Lautenberger JA, Papas TS, Ghrayeb J, Chang NT, Gallo RC, Wong-Staal F: Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313:277, 1985
30. Perkus ME, Limbach K, Paoletti E: Cloning and expression of foreign genes in Vaccinia virus, using a host range selection system. J Virol 63:3829, 1989
31. Nixon DF, McMichael AJ: Cytotoxic T-cell recognition of HIV proteins and peptides AIDS 5:1049, 1991
32. Taylor J, Edbauer C, Rey-Senelonge A, Bouquet J-F, Norton E, Goebel S, Desmettre P, Paoletti E: Newcastle disease virus fusion protein expressed in a Fowlpox virus recombinant confers protection in chickens. J Virol 64:1441, 1990
33. + cells used for adoptive immunotherapy of patients infected with human immunodeficiency virus. Blood 81:2085, 1993
34. Horohov DW, Crim JA, Smith PL, Siegel JP: IL-4 (B cell-stimulatory factor 1) regulates multiple aspects of influenza virus-specific cell-mediated immunity. J Immunol 141:4217, 1988
35. + T lymphocytes. J Immunol 151:2444, 1993
36. Pross HF, Baines MT, Rubin P, Shragge P, Patterson MS: Spontaneous human lymphocyte mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer activity. J Clin Immunol 1:51, 1981
37. + phenotype. J Immunol 146:257, 1991
38. Koup RA, Pikora CA, Luzuriaga K, Brettler DB, Day ES, Mazzara GP, Sullivan JL: Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: In vitro quantitation of effector cell populations with p17 and p24 specificities. J Exp Med 174:1593, 1991
39. de St.Groth F: Reevaluation of limiting dilution assays. J Immunol Methods 49:R11, 1982
40. Stellrecht KA, Sperber K, Pogo BG-T: Stimulation of lymphokines in Jurkat cells persistently infected with vaccinia virus. J Virol 66:2046, 1992
41. + T lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS. Blood 81:2093, 1993
42. Croft M: Activation of naive, memory and effector T cells. Curr Opin Immunol 6:431, 1994
43. Russell JH, Whithe CL, Loh DY, Meleedy-Rey P: Receptor-stimulated death pathway is opened by antigen in mature T cells. Proc Natl Acad Sci USA 88:2151, 1991
44. Carini C, McLane MF, Mayer KH, Essex M: Dysregulation of interleukin-7 receptor may generate loss of cytotoxic T cell response in human immunodeficiency virus type 1 infection. Eur J Immunol 24:2927, 1994
45. Lieberman J, Fabry JA, Shankar P, Beckett L, Skolnik PR: Ex vivo expansion of HIV type 1-specific cytolytic T cells from HIV type 1-seropositive subjects. AIDS Res Hum Retroviruses 11:257, 1995
46. Koenig S, Conley AJ, Brewah YA, Jones GM, Leath S, Boots LJ, Davey V, Pantaleo G, Demarest JF, Carter C, Wannebo C, Yannelli JR, Rosenberg SA, Lane CH: Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med 1:330, 1995
47. + cytotoxic T cells express CD38 and HLA-DR antigens. J Immunol 150:3070, 1993
48. Tyler DS, Lyerly HK, Weinhold KJ: Minireview: Anti-HIV-1 ADCC. AIDS Res Hum Retroviruses 5:557, 1989
49. Lynch DH, Namen AE, Miller RE: In vivo evaluation of the effects of interleukins 2, 4, 7 on enhancing the immunotherapeutic efficacy of anti-tumor cytotoxic T lymphocytes. Eur J Immunol 21:2977, 1991
50. Lotze MT, Zeh HJ, Elder EM, Cai Q, Pippin BA, Rosenstein MM, Whiteside TL, Herberman R: Use of T-cell growth factors (interleukins 2, 4, 7, 10, and 12) in the evaluation of T-cell reactivity to melanoma. J Immunother 12:212, 1992
51. Carini C, Essex M: Interleukin 2-independent interleukin 7 activity enhances cytotoxic immune response of HIV-1-infected individuals. AIDS Res Hum Retroviruses 10:121, 1994
52. Trinchieri G: Interleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 84:4008, 1994
53. + T cells: Their activation and effector functions. Curr Opin Immunol 6:453, 1994
54. + lymphocytes can control HIV infection in vitro suppressing virus replication. Science 234:1563, 1986
55. + T lymphocytes suppresses HIV replication. J Immunol 66:628, 1989
56. + T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: A novel antiviral mechanism. AIDS Res Hum Retroviruses 9:1079, 1993
57. + T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. Proc Natl Acad Sci USA 92:2308, 1995
58. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, DiMarzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau DR: Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661, 1996
59. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667, 1996
60. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, Sodrowski J: The β-chemokine receptors CCR3 and CCR% facilitate infection by primary HIV-1 isolates. Cell 85:1135, 1996
61. Doranz BJ, Rucker J, Yi Y, Smith RJ, Samson M, Peiper SC, Parmentier M, Collman RC, Doms RW: A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85:1149, 1996
62. Toso JF, Chen C-H, Mohr JR, Piglia L, Oei C, Ferrari G, Greenberg ML, Weinhold KJ: Oligoclonal CD8 lymphocytes from person with asymptomatic human immunodeficiency virus (HIV) type 1 infection inhibit HIV-1 replication. J Infect Dis 172:964, 1995
63. + cells: Evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol 71:3120, 1997
64. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, Shaw GM: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117, 1995
65. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123, 1995